PROK

NASD ProKidney Corp. Class A
Sep 30, 2026 · 5:56 AM ET EOD Market Closed

$1.63 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.63, $0.05 below the day’s high of $1.68

YTD change
-27.23%
vs 20-day SMA
-10.23%
vs 200-day SMA
-14.74%

Price ranges

Previous day
$1.61 $1.68
open $1.61 close $1.63
+$0.02 (+1.24%)
Today
$1.61 $1.68
$1.63
Past week
$1.54 $1.86
from $1.78 now $1.63
-$0.15 (-8.17%)
Past month
$1.54 $2.09
from $1.83 now $1.63
-$0.20 (-10.93%)
This year
$1.30 $2.61
from $2.24 now $1.63
-$0.61 (-27.23%)

Price & Performance

+0.01 (+0.62%) / 6M

$1.26$1.59$1.92$2.25Mar 30Jun 30Sep 29

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 88.5% away from all-time highs of $14.19
  • PROK is down 27% since the beginning of the year
  • PROK is down 34% over the past 12 months
  • PROK is down 11% over the past 1 month
  • 21% of all PROK investors are betting against PROK

PROK reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -32.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.15
Earnings momentum +2.7% Quarterly EPS growth
Quarterly change +2.7%

Valuation

P/E ratio N/A
Enterprise value $1.2B
Beta 3.07

Balance sheet & scale

IncomeN/A
Revenue$818.0K
Cash$181.6M
Debt$3.5K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $492.8M

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $423.64 +1.32%
MRNA Moderna, Inc. $203.46 +3.13%
RVMD Revolution Medicines, Inc. $204.48 +1.36%
ROIV Roivant Sciences Ltd. $36.50 -1.30%
BNTX BioNTech SE Sponsored ADR $98.57 -0.51%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.